Moolec Science Secures Path to Regain Nasdaq Compliance by Mid-2026

Moolec Science S.A. (MLEC) has achieved a significant milestone in its regulatory standing after Nasdaq Staff issued a supportive memorandum to the Nasdaq Hearings Panel. The Staff’s recommendation clears the way for the company to regain compliance with Nasdaq’s stockholders’ equity requirement through June 29, 2026, following a series of transformative accounting adjustments completed in late 2025. If the Hearing Panel approves the exception, Moolec intends to meet all conditions outlined in the Staff decision and any additional directives from the Panel.

Nasdaq Staff Backs Compliance Exception Through June 2026

The Nasdaq Staff memorandum highlights the exchange’s acknowledgement of the dramatic strengthening in Moolec’s financial position. The material improvement stems from a sequence of corporate restructuring events that unfolded during the fourth quarter of 2025, which the company believes have already restored its compliance status with the stockholders’ equity threshold.

The company’s efforts to regain its standing were bolstered by several significant developments. On December 26, 2025, Bioceres S.A. initiated bankruptcy proceedings, causing Moolec to lose operational control over Bioceres S.A. and its wholly owned subsidiary, Bioceres LLC. These deconsolidation events generated substantial accounting adjustments: approximately $91.0 million in gains related to the loss of Bioceres S.A. control, plus an additional $5.2 million from the loss of Bioceres LLC control.

Subsidiary Bankruptcies Trigger Major Balance Sheet Restructuring

A third critical restructuring event occurred on December 31, 2025, when Theo I SCSp—a Luxembourg-domiciled special limited partnership—entered bankruptcy proceedings. This triggered Moolec’s loss of control over the entity and produced approximately $4.6 million in additional accounting gains, all recognized in accordance with IFRS 10 standards.

These interconnected derecognition events, combined with the re-recognition of intercompany liabilities that had been eliminated during previous consolidation, alongside the conversion of certain preference shares into ordinary shares, collectively resulted in a substantial expansion of stockholders’ equity on Moolec’s balance sheet. The company contends these developments demonstrate it has already satisfied the compliance requirement, providing the foundation for Nasdaq’s supportive position.

Market Response and Forward Trajectory

The stock performance reflects the company’s volatility over the past year, having traded within a range from $3.08 to $157.05. As of the latest trading update, MLEC is down 4.40%, changing hands at $7.17. The path forward hinges on whether the Nasdaq Hearings Panel will formalize the Staff’s recommendation, allowing Moolec the designated period to fully demonstrate and maintain compliance with exchange standards.